Current Research Studies

Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes

A Study of SCID Disorders 6907

Condition(s): Other

What is the goal of the study?

In this prospective and longitudinal natural history study, the aim is to identify variables that affect long-term outcomes following potentially life-saving Definitive Therapy (DT), which includes either 1) allogeneic hematopoietic cell transplant (HCT), or 2) autologous gene therapy (GT). There are three key periods of time for patients receiving therapy for SCID: 1) the pre-DT period, 2) the early post- DT period, and 3) the late post-DT period when long-term side effects may become apparent.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Lauri Burroughs
Study Team Member: Tina Nguyen, Tina.Nguyen@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.